Last reviewed · How we verify

Nelfinavir and Omeprazole

Pfizer · FDA-approved active Small molecule

This is a combination of nelfinavir (an HIV protease inhibitor) and omeprazole (a proton pump inhibitor), which work through separate mechanisms to inhibit viral protease and reduce gastric acid respectively.

This is a combination of an HIV protease inhibitor (nelfinavir) and a proton pump inhibitor (omeprazole) used together to manage HIV infection and gastric acid-related conditions. Used for HIV-1 infection (nelfinavir component), Gastric acid suppression in HIV patients (omeprazole component).

At a glance

Generic nameNelfinavir and Omeprazole
SponsorPfizer
Drug classHIV protease inhibitor + proton pump inhibitor combination
TargetHIV protease (nelfinavir); H+/K+-ATPase proton pump (omeprazole)
ModalitySmall molecule
Therapeutic areaInfectious Disease; Gastroenterology
PhaseFDA-approved

Mechanism of action

Nelfinavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking viral replication. Omeprazole reduces gastric acid production by inhibiting the proton pump in gastric parietal cells. However, omeprazole can reduce nelfinavir absorption, making this a problematic combination that is generally contraindicated or requires careful management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: